Contributor since: 2016
Latest Articles
Melinta: Dan, Here's Your Coat, What's Your Hurry?
Coke: A Coffee Strategy?
Abuse-Deterrent Opioids: A Business Answer To The Opioid Abuse Crisis
PepsiCo And Gilead: 2 Very Different CEO Departures
Amazon: A Tipping Point For Brick And Mortar Retailers
Starbucks: 3 Letters For Kevin Johnson
Starbucks: The Philadelphia Story: A Misapprehended Reality
Synergy Pharmaceuticals 'Evaluating All Options': Does That Mean A Formal Strategic Review?
Synergy: The Illusion Of Success Or Grounded Potential? A SWOT Analysis
Melinta: Acquisition As Growth Strategy
The New Melinta: A Strategic Difference
Some Early Observations On The Cempra Merger With Melinta
Cempra: Are We There Yet?
The Opioid Abuse Epidemic: What's The Investment Angle?
McDonald's: Learning From Mistakes
PepsiCo: The Soda Tax Is The Opportunity
McDonald's: They Remembered How The Golden Arches Got Built
Synergy: Why The Downgrade?
Cui Bono, Cempra?
PepsiCo: Isn't It Time To Make Shares Less Expensive For The Smaller Investor?
PepsiCo: On M&A, The Hunter, Not The Hunted
Synergy: 3 Scenarios, 1 Choice
Cempra's Electric Kool-Aid Acid Test
Cempra: A Post-CRL Perspective
Starbucks' Success Is Not So Simple
Cempra: The CEO Transition Matters
Cempra: A Revealing SWOT Analysis